Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
SAVA 
Cassava Sciences Inc (SAVA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/09/2025: SAVA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -51.02% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/09/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 84.54M USD | Price to earnings Ratio - | 1Y Target Price 2 |
Price to earnings Ratio - | 1Y Target Price 2 | ||
Volume (30-day avg) - | Beta -2.02 | 52 Weeks Range 1.15 - 42.20 | Updated Date 06/30/2025 |
52 Weeks Range 1.15 - 42.20 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.59 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -59.03% | Return on Equity (TTM) -70.6% |
Valuation
Trailing PE - | Forward PE 151.52 | Enterprise Value -35631025 | Price to Sales(TTM) - |
Enterprise Value -35631025 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -8.26 | Shares Outstanding 48307900 | Shares Floating 43475174 |
Shares Outstanding 48307900 | Shares Floating 43475174 | ||
Percent Insiders 12.79 | Percent Institutions 33.05 |
Upturn AI SWOT
Cassava Sciences Inc
Company Overview
History and Background
Cassava Sciences Inc. (SAVA) is a clinical-stage biotechnology company founded in 2014. Initially focused on developing treatments for neurodegenerative diseases, its primary focus has become Alzheimer's disease. A significant milestone was the initiation of its Phase 2b clinical trial for simufilam, a potential treatment for Alzheimer's. The company has faced scrutiny and legal challenges regarding alleged data manipulation in its research, which it has publicly denied.
Core Business Areas
- Alzheimer's Disease Therapeutics: Cassava Sciences is dedicated to developing novel treatments for Alzheimer's disease. Its lead drug candidate, simufilam, targets the underlying pathology of the disease. The company is also developing a potential treatment for the same disease, SavaDx, a diagnostic test.
Leadership and Structure
The leadership team of Cassava Sciences includes key scientific and executive personnel responsible for clinical development, research, and corporate operations. Specific leadership details can be found on the company's official website and in its SEC filings. The company operates as a typical biotechnology firm with research and development at its core.
Top Products and Market Share
Key Offerings
- simufilam: Simufilam is Cassava Sciences' lead drug candidate for the treatment of Alzheimer's disease. It is a small molecule drug designed to restore the normal shape and function of a protein called filamin A (FLNA), which is implicated in the pathology of Alzheimer's. The company is currently conducting clinical trials to evaluate its safety and efficacy. There is no established market share for simufilam as it is still in clinical development. Key competitors in the Alzheimer's drug market include Biogen (with Aduhelm and Leqembi), Eisai (with Leqembi), and Eli Lilly (with donanemab, currently under review).
- SavaDx: SavaDx is a proprietary diagnostic test developed by Cassava Sciences to detect the presence of a specific form of the protein beta-secretase 1 (BACE1) in blood, which the company believes is an early indicator of Alzheimer's disease. Similar to simufilam, it has no current market share as it is in development. Diagnostic competitors include companies offering PET scans and cerebrospinal fluid (CSF) tests, as well as other companies developing blood-based biomarkers.
Market Dynamics
Industry Overview
The biotechnology industry, particularly the segment focused on neurodegenerative diseases like Alzheimer's, is characterized by high research and development costs, long development cycles, and a high rate of failure. However, it also presents immense potential for significant returns if successful treatments are brought to market, given the large and growing unmet medical need.
Positioning
Cassava Sciences is positioned as a clinical-stage biotechnology company with a novel approach to treating Alzheimer's disease. Its competitive advantage lies in its unique scientific hypothesis and its investigational drug, simufilam, which targets a different mechanism than many other Alzheimer's drugs in development. However, its position is subject to the outcomes of its ongoing clinical trials and ongoing scrutiny regarding its research data.
Total Addressable Market (TAM)
The total addressable market for Alzheimer's disease treatments is substantial and growing, estimated to be in the tens of billions of dollars globally. If simufilam proves effective and gains regulatory approval, Cassava Sciences could capture a significant portion of this market. Its positioning relative to the TAM depends entirely on the successful clinical development and commercialization of its therapies.
Upturn SWOT Analysis
Strengths
- Proprietary scientific hypothesis for Alzheimer's disease.
- Lead drug candidate, simufilam, targeting a novel mechanism.
- Experienced scientific team with expertise in neurodegeneration.
- Potential for a groundbreaking diagnostic test (SavaDx).
Weaknesses
- Clinical-stage company with no approved products.
- Reliance on the success of simufilam clinical trials.
- Past controversies and allegations regarding data integrity, impacting investor confidence.
- Limited financial resources compared to larger pharmaceutical companies.
Opportunities
- Addressing a large and growing unmet medical need in Alzheimer's disease.
- Potential for partnerships or acquisition by larger pharmaceutical companies.
- Advancements in diagnostic technologies to complement therapeutic development.
- Regulatory pathways for accelerated approval of breakthrough therapies.
Threats
- Failure of simufilam in ongoing or future clinical trials.
- Regulatory hurdles and delays in drug approval.
- Intense competition from other pharmaceutical companies developing Alzheimer's treatments.
- Continued reputational damage from past controversies.
- Changes in healthcare policy and reimbursement.
Competitors and Market Share
Key Competitors
- Biogen (BIIB)
- Eisai Co., Ltd. (ESALY)
- Eli Lilly and Company (LLY)
Competitive Landscape
Cassava Sciences' competitive advantages lie in its novel scientific approach to Alzheimer's. However, it faces significant disadvantages against established pharmaceutical giants like Biogen, Eisai, and Eli Lilly, which have vast financial resources, established manufacturing capabilities, extensive clinical trial expertise, and existing market presence in other therapeutic areas. These larger competitors also have multiple drug candidates in various stages of development for Alzheimer's.
Growth Trajectory and Initiatives
Historical Growth: Historically, Cassava Sciences' growth trajectory has been marked by significant scientific advancements and the progression of its drug candidates through the clinical development pipeline. This growth has been punctuated by periods of intense investor interest and stock price appreciation, often followed by sharp declines due to setbacks or controversies.
Future Projections: Future projections for Cassava Sciences are highly dependent on the success of its ongoing clinical trials for simufilam and SavaDx. Analyst estimates, if available, would focus on the potential market penetration of approved therapies and future revenue streams. Without approved products, projections are speculative.
Recent Initiatives: Recent initiatives likely include advancing simufilam through its Phase 2b and potential Phase 3 trials, continuing research and development for SavaDx, and managing ongoing litigation and regulatory interactions. The company also actively engages in investor relations and scientific publications to communicate its progress.
Summary
Cassava Sciences Inc. is a clinical-stage biotechnology company with a high-risk, high-reward profile in the Alzheimer's disease market. Its innovative approach and potential blockbuster drug simufilam are promising, but significant hurdles remain, including the critical need for successful clinical trial outcomes and overcoming past data integrity concerns. The company's future hinges on regulatory approval and market acceptance against well-established competitors.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Cassava Sciences Inc. SEC Filings (10-K, 10-Q, 8-K)
- Company Investor Relations Website
- Reputable Financial News Outlets (e.g., Bloomberg, Reuters, Wall Street Journal)
- Biotechnology Industry Research Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is based on publicly available information as of the current date and is for informational purposes only. It does not constitute financial advice. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. Market share data for clinical-stage companies is often estimated or not directly comparable until products are approved and marketed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cassava Sciences Inc
Exchange NASDAQ | Headquaters Austin, TX, United States | ||
IPO Launch date 2000-07-14 | CEO, President & Director Mr. Richard Jon Barry | ||
Sector Healthcare | Industry Biotechnology | Full time employees 30 | Website https://www.cassavasciences.com |
Full time employees 30 | Website https://www.cassavasciences.com | ||
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.